INGN

Inogen Inc

Add to Watchlist

Advanced Chart

6.800

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

6.870

Open

6.810

VWAP

6.79

Vol

141.79K

Mkt Cap

182.83M

Low

6.690

Amount

963.17K

EV/EBITDA(TTM)

Total Shares

26.89M

63.94M

EV/OCF(TTM)

P/S(TTM)

0.48

Inogen, Inc. is a medical technology company offering respiratory products for use in the homecare setting. It supports patient respiratory care by developing, manufacturing, and marketing portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Its Inogen One and Inogen Rove systems concentrate the air around the patient to offer a source of supplemental oxygen with a battery and can be plugged into an outlet when at home, in a car, or in a public place with outlets available. Its Inogen One and Inogen Rove systems reduce the patient’s reliance on stationary concentrators and scheduled deliveries of tanks with a finite supply of oxygen. Inogen Connect is a wireless connectivity platform for the Inogen One G4, Inogen One G5, Inogen Rove 4, and Inogen Rove 6, consisting of a front-end mobile application for use by long-term oxygen therapy users. It offers Simeox, which is an airway clearance device.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

87.70M

+9.51%

93.27M

+4.99%

90.60M

+2.07%

Estimates Revision

The market is revising Upward the revenue expectations for Inogen, Inc. (INGN) for FY2025, with the revenue forecasts being adjusted by 0.21% over the past three months. During the same period, the stock price has changed by -6.46%.

Revenue Estimates for FY2025

Revise Upward

+0.21%

In Past 3 Month

Stock Price

Go Down

-6.46%

In Past 3 Month

4 Analyst Rating

54.41% Upside

Wall Street analysts forecast INGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INGN is 10.50 USD with a low forecast of 7.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

1 Hold

1 Sell

Hold

54.41% Upside

Current: 6.800

Low

7.00

Averages

10.50

High

14.00

54.41% Upside

Current: 6.800

Low

7.00

Averages

10.50

High

14.00

B. Riley

NULL -> Buy

initiated

$14

2025-06-17

Reason

B. Riley

Price Target

$14

2025-06-17

initiated

NULL -> Buy

Reason

B. Riley initiated coverage of Inogen with a Buy rating and $14 price target.

B. Riley

Anderson Schock

Buy

initiated

$14

2025-06-17

Reason

B. Riley

Anderson Schock

Price Target

$14

2025-06-17

initiated

Buy

Reason

Needham

Hold

Buy

upgrade

$12

2025-05-22

Reason

Needham

Price Target

$12

2025-05-22

upgrade

Hold

Buy

Reason

Needham

Mike Matson

Hold

Reiterates

n/a

2025-04-09

Reason

Needham

Mike Matson

Price Target

n/a

2025-04-09

Reiterates

Hold

Reason

Needham

Mike Matson

Hold

Reiterates

n/a

2025-02-27

Reason

Needham

Mike Matson

Price Target

n/a

2025-02-27

Reiterates

Hold

Reason

Needham

Mike Matson

Hold

Reiterates

n/a

2025-02-26

Reason

Needham

Mike Matson

Price Target

n/a

2025-02-26

Reiterates

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Inogen Inc (INGN.O) is -6.29, compared to its 5-year average forward P/E of -824.61. For a more detailed relative valuation and DCF analysis to assess Inogen Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-824.61

Current PE

-6.29

Overvalued PE

2749.19

Undervalued PE

-4398.41

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

14.66

Current EV/EBITDA

-498.81

Overvalued EV/EBITDA

163.54

Undervalued EV/EBITDA

-134.21

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

1.52

Current PS

0.50

Overvalued PS

2.66

Undervalued PS

0.39

Financials

Annual

Quarterly

FY2025Q1

YoY :

+5.45%

82.28M

Total Revenue

FY2025Q1

YoY :

-50.50%

-7.66M

Operating Profit

FY2025Q1

YoY :

-57.65%

-6.17M

Net Income after Tax

FY2025Q1

YoY :

-59.68%

-0.25

EPS - Diluted

FY2025Q1

YoY :

+112.05%

-18.83M

Free Cash Flow

FY2025Q1

YoY :

+0.36%

44.21

Gross Profit Margin - %

FY2025Q1

YoY :

-23.24%

-6.21

FCF Margin - %

FY2025Q1

YoY :

-59.85%

-7.50

Net Margin - %

FY2025Q1

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

125.2K

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

1.0M

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

125.2K

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

INGN News & Events

Events Timeline

2025-05-07 (ET)

2025-05-07

17:23:41

Inogen reports Q1 EPS (25c) vs. (62c) last year

2025-02-25 (ET)

2025-02-25

16:31:22

Inogen sees FY25 revenue $352M-$355M, consensus $344.55M

2025-02-25

16:30:37

Inogen reports Q4 EPS (41c) vs ($1.14) last year

News

3.0

07-17Newsfilter

Inogen to Report Second Quarter 2025 Financial Results on August 7, 2025

5.0

06-23Newsfilter

Inogen Introduces Voxi 5 Stationary Oxygen Concentrator: Setting a New Standard in Affordable, Durable Oxygen Therapy

4.0

06-16Benzinga

B. Riley Securities Initiates Coverage On Inogen with Buy Rating, Announces Price Target of $14

People Also Watch

Helix Acquisition Corp II

Gorilla Technology Group Inc

Transcontinental Realty Investors Inc

Heron Therapeutics Inc

Eagle Point Income Company Inc

Alliance Entertainment Holding Corp

5.625

USD

-7.71%

FAQ

What is Inogen Inc (INGN) stock price today?

The current price of INGN is 6.8 USD — it has increased 0 % in the last trading day.

INGN

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

INGN News & Events

Events Timeline

News

People Also Watch

FAQ

What is Inogen Inc (INGN) stock price today?

What is Inogen Inc (INGN)'s business?

What is the price predicton of INGN Stock?

What is Inogen Inc (INGN)'s revenue for the last quarter?

What is Inogen Inc (INGN)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Inogen Inc (INGN)'s fundamentals?

How many employees does Inogen Inc (INGN). have?

What is Inogen Inc (INGN) market cap?